Chapter 6.4 Microdialysis as a method to study blood-brain barrier transport mechanisms

Handbook of Behavioral Neuroscience

Volumn 16, Issue , 2006, Pages 545-572

  de Lange, Elizabeth C M ^a  

^a LEIDEN UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 67649742276     PISSN: 15697339     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S1569-7339(06)16029-4     Document Type: Review

References (216)

1. Abbott N.J. Astrocyte-endothelial interactions and blood-brain barrier permeability. J. Anat. 200 6 (2002) 629-638
2. Abbott N.J., and Revest P.A. Control of brain endothelial permeability. Cerebrovasc. Brain Met. Rev. 3 (1991) 39-72
3. Abbott N.J., Ronnback L., and Hansson E. Astrocyte-endothelial interactions at the blood-brain barrier. Nat. Rev. Neurosci. 7 1 (2006) 41-53
4. Agon P., Braeckman R., Van Haver D., Denutte H., Goethals P., Donche -H., Vermeullen F., Deman J., and Kaufman J.M. Drug distribution in dog brain studied by positron emission tomography. Biopharm. Drug. Dispos. 9 (1988) 567-577
5. Agon P., Goethals P., van Haver D.K., and Kaufman J.M. Permeability of BBB for atenolol studies by PET. J. Pharm. Pharmacol. 43 (1991) 597-600
6. Aird R.B. A study of intrathecal, cerebrospinal fluid-to-brain exchange. Exp. Neurol. 86 (1984) 342-358
7. Allen D.D., Crooks P.A., and Yokel R.A. 4-Trimethylammonium antipyrine: a quaternary ammonium nonradionuclide marker for blood-brain barrier integrity during in vivo microdialysis. J. Pharmacol. Toxicol. Methods 28 3 (1992) 129-135
8. Arthur F.E., Shivers R.R., and Bowman P.D. Astrocyte-mediated induction of tight junctions in brain capillary endothelium, an efficient in vitro model. Brain Res. 433 1 (1987) 155-159
9. Banks W.A. Physiology and pathology of the blood-brain barrier, implications for microbial pathogenesis, drug delivery and neurodegenerative disorders. J. Neurovirol. 5 (1999) 538-555
10. 19F nuclear magnetic resonance spectroscopy of neuroleptics, the first in vivo pharmacokinetics of trifluoperazine in the rat brain and the first in vivo spectrum of fluphenazine in the human brain. Biol. Psychiatry. 30 (1991) 656-662
11. Beagles K.E., Morrison P.F., and Heyes M.P. Quinolinic acid in vivo synthesis rates, extracellular concentrations, and intercompartmental distributions in normal and immune-activated brain as determined by multiple-isotope microdialysis. J. Neurochem. 70 1 (1998) 281-291
12. Beck D.W., Vinters H.V., Hart M.N., and Cancilla P.A. Glial cells influence polarity of the blood-brain barrier. J. Neuropathol. Exp. Neurol. 43 3 (1984) 219-224
13. Begley D.J. ABC transporters and the blood-brain barrier. Curr. Pharm. Des. 10 12 (2004) 1295-1312
14. Belinsky M.G., Chen Z.-.S., Shchaveleva I., Zeng H., and Kruh G.D. Characterization of the drug resistance and transport properties of multidrug resistance protein 6 (MRP6, ABCC6). Cancer Res. 62 (2002) 6172-6177
15. Bendayan R., Lee G., and Bendayan M. Functional expression and localization of P-glycoprotein at the blood brain barrier. Microsc. Res. Tech. 57 5 (2002) 365-380
16. Benveniste H., and Diemer N.H. Cellular reactions to implantation of a microdialysis tube in the rat hippocampus. Acta Neuropath. (Berl.) 74 (1987) 234-238
17. Benveniste H., Drejer J., Schoesboe A., and Diemer N.H. Elevation of the extracellular concentrations of glutamate and aspartate in rat hippocampus during transient cerebral ischemia monitored by intracerebral microdialysis. J. Neurochem. 43 (1984) 1369-1374
18. Benveniste H., Drejer J., Schoesboe A., and Diemer N.H. Regional cerebral glucose phosphorylation and blood flow after insertion of a microdialyis fiber through the dorsal hippocampus in the rat. J. Neurochem. 49 (1987) 729-734
19. Bickel U. How to measure drug transport across the blood-brain barrier. NeuroRx 2 1 (2005) 15-26
20. Blasberg R.G., Kobayashi T., Patlak C.S., Shinohara M., Miyoaka M., Rice J.M., and Shapiro W.R. Regional blood flow, capillary permeability, and glucose utilization in two brain tumor models, preliminary observations and pharmacokinetic implications. Cancer Treat. Rep. 65 Suppl 2 (1981) 3-12
21. Bodor N., and Brewster M.E. Problems of drug delivery of drugs to the brain. Pharma. Ther. 19 (1983) 337-386
22. Bolwig T.G., Hertz M.M., Paulson O.B., Spotoft H., and Rafaelsen O.J. The permeability of the blood-brain barrier during electrically induced seizures in man. Eur. J. Clin. Invest. 7 (1977) 87-93
23. Bonate P.L. Animal models for studying transport across the blood-brain barrier. J. Neurosci. Methods 56 1 (1995) 1-15
24. Borst P., Evers R., Kool M., and Wijnholds J. A family of drug transporters, the multidrug resistance-associated proteins. J. Natl. Cancer Inst. 2 16 (2000) 1295-1302
25. Borst P., and Oude Elferink R. Mammalian ABC transporters in health and disease. Annu. Rev. Biochem. 71 (2002) 537-592
26. Bouman H.J., and Van Wimersma Greidanus T.B. A rapid and simple cannulation technique for repeated sampling of cerebrospinal fluid in freely moving rats. Brain Res. Bull. 4 4 (1979) 575-577
27. Bourasset F., Bernard K., Munoz C., Genissel P., and Scherrmann J.M. Neuropharmacokinetics of a new alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA) modulator, S18986 [(S)-2,3-dihydro-[3,4]cyclopentano-1,2,4-benzothiadiazine-1,1-dioxide], in the rat. Drug Metab. Dispos. 33 8 (2005) 1137-1143
28. Bouw R., Ederoth P., Lundberg J., Ungerstedt U., Nordstrom C.H., and Hammarlund-Udenaes M. Increased blood-brain barrier permeability of morphine in a patient with severe brain lesions as determined by microdialysis. Acta Anaesthesiol. Scand. 45 (2001) 390-392
29. Bouw M.R., Gardmark M., and Hammarlund-Udenaes. M. Pharmacokinetic-pharmacodynamic modelling of morphine transport across the blood-brain barrier as a cause of the antinociceptive effect delay in rats - a microdialysis study. Pharm. Res. 17 10 (2000) 1220-1227
30. Bouw M.R., Xie R., Tunblad K., and Hammarlund-Udenaes M. Blood-brain barrier transport and brain distribution of morphine-6-glucuronide in relation to the antinociceptive effect in rats - pharmacokinetic/pharmacodynamic modelling. Br. J. Pharmacol. 134 8 (2001) 1796-1804
31. Bradbury M.W. The structure and function of the blood-brain barrier. Fed. Proc. 43 2 (1984) 186-190
32. Brightman M.W. Morphology of blood-brain interfaces. Exp. Eye Res. 25 Suppl. (1977) 1-25
33. Brightman M.W., Zis K., and Anders J. Morphology of cerebral endothelium and astrocytes as determinants of the neuronal microenvironment. Acta Neuropathol. Suppl. (Berl.) 8 (1983) 21-33
34. Brosman C.F., and Claudio L. Brain microvasculature in multiple sclerosis. In: Pardridge W.M. (Ed). Introduction to the Blood-Brain Barrier; Methodology, Biology and Pathology (1998), Cambridge University Press, Cambridge, UK 386-400
35. Bungay P.M., Morrison P.F., and Dedrick R.L. Steady-state theory for quantitative microdialysis of solutes and water in vivo and in vitro. Life Sci. 46 (1990) 105-119
36. Cancilla P.A., and DeBault L.E. Neutral amino acid transport properties of cerebral endothelial cells in vitro. J. Neuropathol. Exp. Neurol. 42 2 (1983) 191-199
37. Chen Z.-.S., Hopper Borge E., Belinsky M.G., Shchaveleva I., Kotova E., and Kruh G.D. Characterization of the transport properties of human multidrug resistance protein 7 (MRP7, ABCC10). Mol. Pharmacol. 63 (2003) 351-358
38. Chenel M., Marchand S., Dupuis A., Lamarche I., Paquereau J., Pariat C., and Couet W. Simultaneous central nervous system distribution and pharmacokinetic-pharmacodynamic modelling of the electroencephalogram effect of norfloxacin administered at a convulsant dose in rats. Br. J. Pharmacol. 142 2 (2004) 323-330
39. Clinckers R., Smolders I., Meurs A., Ebinger G., and Michotte Y. Quantitative in vivo microdialysis study on the influence of multidrug transporters on the blood-brain barrier passage of oxcarbazepine, concomitant use of hippocampal monoamines as pharmacodynamic markers for the anticonvulsant activity. J. Pharmacol. Exp. Ther. 314 2 (2005) 725-731
40. Coleman D.L., King R.N., and Anrade J.D. The foreign body reaction, a chronic inflammatory response. J. Biomed. Mater. Res. 8 (1974) 199-211
41. Collins J.M., and Dedrick L.D. Distributed model for drug delivery to CSF and brain tissue. J. Am. Physiol. 14 (1983) R303-R310
42. Cooray H.C., Blackmore C.G., Maskell L., and Barrand M.A. Localisation of breast cancer resistance protein in microvessel endothelium of human brain. Neuroreport 13 16 (2002) 2059-2063
43. Cordon-Cardo, B., O'Brien, J.P., Casals, D., Rittman-Grauer, L., Biedler, J.L., Melamed, M.R. and Bertino, J.R. (1989) Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites. Proc. Natl. Acad. Sci. U.S.A., 86: 695-689.
44. Cornford E.M. The blood-brain barrier: a dynamic regulatory interface. Mol. Physiol. 7 (1985) 219-260
45. Cornford E.M. Epilepsy and the blood-brain barrier, endothelial cell responses to seizures. Adv. Neurol. 79 (1999) 845-862
46. Cornford E.M., and Cornford M.E. New systems for delivery of drugs to the brain in neurological disease. Lancet Neurol. 1 5 (2002) 306-315
47. Cserr H.F. Convection of brain interstitial fluid. In: Shapiro K., Marmarou A., and Portnoy H. (Eds). Hydrocephalus (1984), Raven Press, New York 59-68
48. Dash A.K., and Elmquist W.F. Separation methods that are capable of revealing blood-brain barrier permeability. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 797 1-2 (2003) 241-254
49. Davson H., and Welch K. The permeation of several materials into the fluids of the rabbit's brain. J. Physiol. 218 2 (1971) 337-351
50. de Boer A.G., van der Sandt I., and Gaillard P.J. The role of drug transporters at the blood-brain barrier. Ann. Rev. Pharmacol. Toxicol. 43 (2003) 629-656
51. de Graaf R.A., Pan J.W., Telang F., Lee J.H., Brown P., Novotny E.J., Hetherington H.P., and Rothman D.L. Differentiation of glucose transport in human brain gray and white matter. J. Cereb. Blood Flow Metab. 21 5 (2001) 483-492
52. de Lange E.C., and Danhof M. Considerations in the use of cerebrospinal fluid pharmacokinetics to predict brain target concentrations in the clinical setting, implications of the barriers between blood and brain. Clin. Pharmacokinet. 41 10 (2002) 691-703
53. de Lange E.C., Danhof M., de Boer A.G., and Breimer D.D. Methodological considerations of intracerebral microdialysis in pharmacokinetic studies on drug transport across the blood-brain barrier. Brain Res. Rev. 25 1 (1997) 27-49
54. de Lange E.C., de Bock G., Schinkel A.H., de Boer A.G., and Breimer D.D. BBB transport and P-glycoprotein functionality using MDR1A (-/-) and wild-type mice. Total brain versus microdialysis concentration profiles of rhodamine-123. Pharm. Res. 15 (1998) 1657-1665
55. de Lange E.C., de Boer B.A., and Breimer D.D. Microdialysis for pharmacokinetic analysis of drug transport to the brain. Adv. Drug Deliv. Rev. 36 2-3 (1999) 211-227
56. de Lange E.C., de Boer A.G., and Breimer D.D. Methodological issues in microdialysis sampling for pharmacokinetic studies. Adv. Drug Deliv. Rev. 45 2-3 (2000) 125-148
57. de Lange E.C., Marchand S., van den Berg D., van der Sandt I.C., de Boer A.G., Delon A., Bouquet S., and Couet W. In vitro and in vivo investigations on fluoroquinolones; effects of the P-glycoprotein efflux transporter on brain distribution of sparfloxacin. Eur. J. Pharm. Sci. 12 2 (2000) 85-93
58. de Lange E.C., Ravenstijn P.G., Groenendaal D., and van Steeg T.J. Toward the prediction of CNS drug-effect profiles in physiological and pathological conditions using microdialysis and mechanism-based pharmacokinetic-pharmacodynamic modeling. AAPS J. 7 3 (2005) E532-E543
59. de Lange E.C.M., Danhof M., De Boer A.G., and Breimer D.D. Critical factors of intracerebral microdialysis as a technique to determine the pharmacokinetics of drugs in rat brain. Brain Res. 666 (1994) 1-8
60. de Lange E.C.M., de Boer A.G., and Breimer D.D. Monitoring in vivo blood-brain barrier drug transport, cerebrospinal fluid sampling, the unit impulse response method and, with special reference, intracerebral microdialysis. STP Pharma. Sci. 7 (1997) 17-27
61. de Lange E.C.M., De Vries J.D., Zurcher C., Danhof M., De Boer A.G., and Breimer D.D. The use of intracerebral microdialysis for the determination of pharmacokinetic profiles of anticancer drugs in tumor-bearing rat brain. Pharm. Res. 12 (1995) 1924-1931
62. de Lange E.C.M., Hesselink M.B., Danhof M., De Boer A.G., and Breimer D.D. The use of intracerebral microdialysis to determine changes in blood-brain barrier transport. Pharm. Res. 12 12 (1995) 1924-1931
63. de Lange E.C.M., Zurcher C., Danhof M., De Boer A.G., and Breimer D.D. Repeated microdialysis perfusions, periprobe tissue reactions and BBB permeability. Brain Res. 702 (1995) 261-265
64. de Vries H.E., Kuiper J., de Boer A.G., van Berkel T.J.C., and Breimer D.D. The role of the blood-brain barrier in neuro-inflammatory diseases. Pharmacol. Rev. 49 (1997) 143-156
65. Dean M., Rzhetsky A., and Allikmets R. The human ATP-binding cassette (ABC) transporter superfamily. Genome Res. 11 7 (2001) 1156-1166
66. Deguchi Y. Application of in vivo brain microdialysis to the study of blood-brain barrier transport of drugs. Drug Metab. Pharmacokinet. 17 5 (2002) 395-407
67. Deguchi Y., and Morimoto K. Application of an in vivo brain microdialysis technique to studies of drug transport across the blood-brain barrier. Curr. Drug Metab. 2 4 (2001) 411-423
68. Deguchi Y., Yokoyama Y., Sakamoto T., Hayashi H., Naito T., Yamada S., and Kimura R. Brain distribution of 6-mercaptopurine is regulated by the efflux transport system in the blood-brain barrier. Life Sci. 66 7 (2000) 649-662
69. Diserbo M., Agin A., Lamproglou I., Mauris J., Staali F., Multon E., and Amourette C. Blood-brain barrier permeability after gamma whole-body irradiation, an in vivo microdialysis study. Can. J. Physiol. Pharmacol. 80 7 (2002) 670-678
70. Dombrowski S.M., Desai S.Y., Marroni M., Cucullo L., Goodrich K., Bingaman W., Mayberg M.R., Bengez L., and Janigro D. Overexpression of multiple drug resistance genes in endothelial cells from patients with refractory epilepsy. Epilepsia 42 12 (2001) 1501-1506
71. Ederoth P., Tunblad K., Bouw R., Lundberg C.J., Ungerstedt U., Nordstrom C.H., and Hammarlund-Udenaes M. Blood-brain barrier transport of morphine in patients with severe brain trauma. Br. J. Clin. Pharmacol. 57 4 (2004) 427-435
72. Eisenblatter T., Huwel S., and Galla H.J. Characterisation of the brain multidrug resistance protein (BMDP/ABCG2/BCRP) expressed at the blood-brain barrier. Brain Res. 971 2 (2003) 221-231
73. Elsinga P.H., Hendrikse N.H., Bart J., Vaalburg W., and van Waarde A. PET studies on P-glycoprotein function in the blood-brain barrier: how it affects uptake and binding of drugs within the CNS. Curr. Pharma. Des. 10 13 (2004) 1493-1503
74. Feng M.R., Turluck D., Burleigh J., Lister R., Fan C., Middlebrook A., Taylor C., and Su T. Brain microdialysis and PK/PD correlation of pregabalin in rats. Eur. J. Drug Metab. Pharmacokinet. 26 1-2 (2001) 123-128
75. Fenstermacher J.D., Patlak C.S., and Blasberg R.G. Transport of material between brain extracellular fluid, brain cells and blood. Fed. Proc. 33 (1974) 2070-2074
76. Fenstermacher J.D., Wei L., Acuff V., Lin S.Z., Chen J.L., Bereczki D., Otsuka T., Nakata H., Tajima A., Hans F.J., Ghersi-Egea J.F., Finnegan W., Richardson G., Haspel H., and Patlak C. The dependency of influx across the blood-brain barrier on blood flow and the apparent flow-independence of glucose influx during stress. In: Greenwood J., Begley D.J., and Segal M. (Eds). New Concepts of a Blood-Brain Barrier (1995), Plenum Press, New York and London 89-101
77. Foster K.A., and Roberts M.S. Experimental methods for studying drug uptake in the head and brain. Curr. Drug Metab. 1 4 (2000) 333-356
78. Fox E., Bungay P.M., Bacher J., McCully C.L., Dedrick R.L., and Balis F.M. Zidovudine concentration in brain extracellular fluid measured by microdialysis, steady-state and transient results in rhesus monkey. J. Pharmacol. Exp. Ther. 301 3 (2002) 1003-1011
79. Gao B., Hagenbuch B., Kullak-Ublick G.A., Benke D., Aguzzi A., and Meier P.J. Organic anion-transporting polypeptides mediate transport of opioid peptides across blood-brain barrier. J. Pharmacol. Exp. Ther. 294 1 (2000) 73-79
80. Gibbs J.P., Adeyeye M.C., Yang Z., and Shen D.D. Valproic acid uptake by bovine brain microvessel endothelial cells, role of active efflux transport. Epilepsy Res. 58 1 (2004) 53-66
81. Gloor S.M., Wachtel M., Bolliger M.F., Ishihara H., Landmann R., and Frei K. Molecular and cellular permeability control at the blood-brain barrier. Brain Res. Brain Res. Rev. 36 2-3 (2001) 258-264
82. Greig N.H., Momma S., Sweeney D.J., Smith Q.R., and Rapoport S.I. Facilitated transport of melphalan at the rat blood-brain barrier by the large neutral amino acid carrier system. Cancer Res. 47 (1987) 1571-1576
83. Groothuis D.R., and Levy R.M. The entry of antiviral and antiretroviral drugs into the central nervous system. J. Neurovirol. 3 6 (1997) 387-400
84. Groothuis D.R., Molnar P., and Blasberg R.G. Regional blood flow and blood-to-tissue transport in five brain tumor models. Prog. Exp. Tumor Res. 27 (1984) 132-153
85. Groothuis D.R., Ward S., Schlageter K.E., Itskovich A.C., Schwerin S.C., Allen C.V., Dills C., and Levy R.M. Changes in blood-brain barrier permeability associated with insertion of brain cannulas and microdialysis probes. Brain Res. 803 1-2 (1998) 218-230
86. Gross P.M., Sposito N.M., Pettersen S.E., and Fenstermacher J.D. Differences in function and structure of the capillary endothelium in gray matter, white matter, and a circumventricular organ of rat brain. Blood Vessels 23 (1986) 261-270
87. Gupta A., Chatelain P., Massingham R., Jonsson E.N., and Hammarlund-Udenaes M. Brain distribution of cetirizine enantiomers, comparison of three different tissue-to-plasma partition coefficients, K(p), K(p,u), and K(p,uu). Drug Metab. Dispos. 34 2 (2006) 318-323
88. Hammarlund-Udenaes M. The use of microdialysis in CNS drug delivery studies. Pharmacokinetic perspectives and results with analgesics and antiepileptics. Adv. Drug Deliv. Rev. 45 2-3 (2000) 283-294
89. Hammarlund-Udenaes M., Paalzow L.N., and De Lange E.C.M. Drug equilibration across the blood-brain-barrier - pharmacokinetic considerations based on the microdialysis method. Pharm. Res. 14 (1997) 128-134
90. Hardebo J.E., Nilsson B., and Oldendorf W.H. Measurement of brain uptake of radiolabelled substances using a tritiated water internal standard. Brain Res. 24 (1970) 372-376
91. Hasegawa H., Ushio Y., Hayakawa T., Yamada K., and Mogami H. Changes of the blood-brain barrier in experimental metastatic brain tumors. J. Neurosurg. 59 (1983) 304-310
92. Hipfner D.R., Deeley R.G., and Cole S.P. Structural, mechanistic and clinical aspects of MRP1. Biochim. Biophys. Acta 1461 2 (1999) 359-376
93. Higgins C.F. ABC transporters: physiology, structure and mechanisms - an overview. Res. Microbiol 152 3-4 (2001) 205-210
94. Hopper E., Belinsky M.G., Zeng H., Tosolini A., Testa J.R., and Kruh G.D. Analysis of the structure and expression pattern of MRP7 (ABCC10): a new member of the MRP subfamily. Cancer Lett. 162 (2001) 181-191
95. Huai-Yun H., Secrest D.T., Mark K.S., Carney D., Brandquist C., Elmquist W.F., and Miller D.W. Expression of multidrug resistance-associated protein (MRP) in brain microvessel endothelial cells. Biochem. Biophys. Res. Commun. 243 3 (1998) 816-820
96. Huber J.D., Egleton R.D., and Davis T.P. Molecular physiology and pathophysiology of tight junctions in the blood-brain barrier. Trends Neurosci. 24 (2001) 719-725
97. Imperato A., and Di Chiara G. Trans-striatal dialysis coupled to reverse phase high performance liquid chromatography with electrochemical detection: a new method for the study of in vivo release of endogenous dopamine and metabolites. J. Neurosci. 4 (1984) 966-977
98. Imperato A., and Di Chiara G. Dopamine release and metabolism in awake rats after systemic neuroleptics as studied by trans-striatal dialysis. J. Neurosci. 5 (1985) 297-306
99. Inano A., Sai Y., Nikaido H., Hasimoto N., Asano M., Tsuji A., and Tamai I. Acetyl-l-carnitine permeability across the blood-brain barrier and involvement of carnitine transporter OCTN2. Biopharm. Drug Dispos. 24 8 (2003) 357-365
100. Jacob R.J., Fan X., Evans M.L., Dziura J., and Sherwin R.S. Brain glucose levels are elevated in chronically hyperglycemic diabetic rats, no evidence for protective adaptation by the blood brain barrier. Metabolism 51 12 (2002) 1522-1524
101. Jedlitschky G., Leier I., Buchholz U., Barnouin K., Kurz G., and Keppler D. Transport of glutathione, and sulfur conjugates by the MRP gene-encoded conjugate export pump. Cancer Res. 56 (1996) 988-994
102. Kakee A., Terasaki T., and Sugiyama Y. Brain efflux index as a novel method of analyzing efflux transport at the blood-brain barrier. J. Pharmacol. Exp. Ther. 277 3 (1996) 1550-1559
103. Karssen A.M., Meijer O.C., van der Sandt I.C., De Boer A.G., De Lange E.C., and De Kloet E.R. The role of the efflux transporter P-glycoprotein in brain penetration of prednisolone. J. Endocrinol. 175 1 (2002) 251-260
104. Karssen A.M., Meijer O.C., van der Sandt I.C., Lucassen P.J., de Lange E.C., de Boer A.G., and de Kloet E.R. Multidrug resistance P-glycoprotein hampers the access of cortisol but not of corticosterone to mouse and human brain. Endocrinology 142 6 (2001) 2686-2694
105. Kikuchi R., Kusuhara H., Sugiyama D., and Sugiyama Y. Contribution of organic anion transporter 3 (Slc22a8) to the elimination of p-aminohippuric acid and benzylpenicillin across the blood-brain barrier. J. Pharmacol. Exp. Ther. 311 3 (2004) 1147-1153
106. Kim K.S., Wass C.A., and Cross A.S. Blood-brain barrier permeability during the development of experimental bacterial meningitis in the rat. Exp. Neurol. 145 (1997) 253-257
107. Kim R.B. Drugs as P-glycoprotein substrates, inhibitors, and inducers. Drug Metab. Rev. 34 1-2 (2002) 47-54
108. Kim R.B., Fromm M.F., Wandel C., Leake B., Wood A.J.J., Roden D.M., and Wilkinson G.R. The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV1 protease inhibitors. J. Clin. Invest. 101 (1998) 289-294
109. Klopman G., Leming M.S., and Avner R. Quantitative structure-activity relationship of multidrug resistance reversal agents. Mol. Pharmacol. 52 (1997) 323-334
110. Kusuhara H., He Z., Nagata Y., Nozaki Y., Ito T., Masuda H., Meier P.J., Abe T., and Sugiyama Y. Expression and functional involvement of organic anion transporting polypeptide subtype 3 (Slc21a7) in rat choroid plexus. Pharm. Res. 20 5 (2003) 720-727
111. Kusuhara H., and Sugiyama Y. Efflux transport systems for drugs at the blood-brain barrier and blood-cerebrospinal fluid barrier (Part 1). Drug Discov. Today 6 3 (2001) 150-156
112. Kusuhara H., and Sugiyama Y. Efflux transport systems for drugs at the blood-brain barrier and blood-cerebrospinal fluid barrier (Part 2). Drug Discov. Today 6 4 (2001) 206-212
113. Kusuhara H., and Sugiyama Y. Active efflux across the blood-brain barrier, role of the solute carrier family. NeuroRx 2 1 (2005) 73-85
114. Lam F.C., Liu R., Lu P., Shapiro A.B., Renoir J.M., Sharom F.J., and Reiner P.B. Beta-amyloid efflux mediated by p-glycoprotein. J. Neurochem. 76 4 (2001) 1121-1128
115. Larsson C.I. The use of an "internal standard" for control of the recovery in microdialysis. Life Sci. 49 (1991) 73-78
116. Lee G., Dallas S., Hong M., and Bendayan R. Drug transporters in the central nervous system, brain barriers and brain parenchyma considerations. Pharmacol. Rev. 53 (2001) 569-596
117. Lerma J., Herranz A.S., Herreras O., Abraira V., and Del Rio R. In vivo determination of extracellular concentrations of amino acids in the rat hippocampus. A method based on brain dialysis and computerized analysis. Brain Res. 384 (1986) 145-155
118. Leslie E.M., Deeley R.G., and Cole S.P. Toxicological relevance of the multidrug resistance protein 1, MRP1 (ABCC1) and related transporters. Toxicology 167 1 (2001) 3-23
119. Letrent S.P., Pollack G.M., Brouwer K.R., and Brouwer K.L. Effects of a potent and specific P-glycoprotein inhibitor on the blood-brain barrier distribution and antinociceptive effect of morphine in the rat. Drug Metab. Dispos. 27 7 (1999) 827-834
120. Levin V.A. Relationship of octanol/water partition coefficient and molecular weight to rat brain capillary permeability. J. Med. Chem. 23 (1980) 682-684
121. L'Heureux R., Dennis T., Curet O., and Scatton B. Measurement of endogenous noradrenaline release in the rat cerebral cortex in vivo by transcortical dialysis: effects of drugs affecting noradrenergic transmission. J. Neurochem. 46 (1986) 1794-1801
122. Linden K., Stahle L., Ljungdahl-Stahle E., and Borg N. Effect of probenecid and quinidine on the transport of alovudine (3′-fluorothymidine) to the rat brain studied by microdialysis. Pharmacol. Toxicol. 93 5 (2003) 226-232
123. Lo E.H., Singhal A.B., Torchilin V.P., and Abbott N.J. Drug delivery to damaged brain. Brain Res. Brain Res. Rev. 38 (2001) 140-148
124. Lonnroth P., Jansson P.A., and Smith U. A microdialysis method allowing characterization of intercellular water space in humans. Am. J. Physiol. 253 Endocrinol.Metab. 16 (1987) E228-E231
125. Loscher W., and Potschka H. Blood-brain barrier active efflux transporters, ATP-binding cassette gene family. NeuroRx 2 1 (2005) 86-98
126. Lossinsky A.S., and Shivers R.R. Structural pathways for macromolecular and cellular transport across the blood-brain barrier during inflammatory conditions. Histol. Histopathol. 19 2 (2004) 535-564
127. Luer M.S., Hamani C., Dujovny M., Gidal B., Cwik M., Deyo K., and Fischer J.H. Saturable transport of gabapentin at the blood-brain barrier. Neurol. Res. 21 6 (1999) 559-562
128. Mahar Doan K.M., Humphreys J.E., Webster L.O., Wring S.A., Shampine L.J., Serabjit-Singh C.J., Adkison K.K., and Polli J.W. Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs. J. Pharmacol. Exp. Ther. 303 3 (2002) 1029-1037
129. Major O., Shdanova T., Duffek L., and Nagy Z. Continuous monitoring of blood-brain barrier opening to Cr51-EDTA by microdialysis following probe injury. Acta Neurochir. Suppl. (Wien) 51 (1990) 46-48
130. Mano Y., Higuchi S., and Kamimura H. Investigation of the high partition of YM992, a novel antidepressant, in rat brain - in vitro and in vivo evidence for the high binding in brain and the high permeability at the BBB. Biopharm. Drug Dispos. 23 9 (2002) 351-360
131. Mans A.M., DeJoseph M.R., Davis D.W., and Hawkins R.A. Regional amino acid transport into brain during diabetes: effect of plasma amino acids. Am. J. Physiol. 253 5 Pt 1 (1987) E575-E583
132. Matlaga B.F., Yasenchak L.P., and Salthouse T.H. Tissue response to implanted polymers: the significance of sample shape. J. Biomed. Mater. Res. 10 (1976) 391-397
133. Mayer U., Wagenaar E., Dorobek B., Beijnen J.H., Borst P., and Schinkel A.H. Full blockade of intestinal P-glycoprotein and extensive inhibition of blood-brain barrier P-glycoprotein by oral treatment of mice with PSC833. J. Clin. Invest. 100 (1997) 2430-2436
134. Mayhan W.G. Regulation of blood-brain barrier permeability. Microcirculation 8 (2001) 89-104
135. McNay E.C., and Sherwin R.S. From artificial cerebro-spinal fluid (aCSF) to artificial extracellular fluid (aECF): microdialysis perfusate composition effects on in vivo brain ECF glucose measurements. J. Neurosci. Methods 132 1 (2004) 35-43
136. Miller D.S., Graeff C., Droulle L., Fricker S., and Fricker G. Xenobiotic efflux pumps in isolated fish brain capillaries. Am. J. Physiol. Regul. Integr. Comp. Physiol. 282 1 (2002) R191-R198
137. Miller D.S., Nobmann S.N., Gutmann H., Toeroek M., Drewe J., and Fricker G. Xenobiotic transport across isolated brain microvessels studied by confocal microscopy. Mol. Pharmacol. 58 6 (2000) 1357-1367
138. Minakawa T., Bready J., Berliner J., Fisher M., and Cancilla P.A. In vitro interaction of astrocytes and pericytes with capillary-like structures of brain microvessel endothelium. Lab. Invest. 65 1 (1991) 32-40
139. Moghaddam B., and Bunney B.S. Ionic composition of microdialysis perfusing solution alters the pharmacological responsiveness and basal outflow of striatal dopamine. J. Neurochem. 53 (1989) 652-654
140. Mooradian A.D. Effect of aging on the blood-brain barrier. Neurobiol. Aging 9 1 (1988) 31-39
141. Morgan M.E., Singhal D., and Anderson B.D. Quantitative assessment of blood-brain barrier damage during microdialysis. J. Pharmacol. Exp. Ther. 277 2 (1996) 1167-1176
142. Mori S., Takanaga H., Ohtsuki S., Deguchi T., Kang Y.S., Hosoya K., and Terasaki T. Rat organic anion transporter 3 (rOAT3) is responsible for brain-to-blood efflux of homovanillic acid at the abluminal membrane of brain capillary endothelial cells. J. Cereb. Blood Flow Metab. 23 (2003) 432-440
143. Morrison P.F., Bungay P.M., Hsiao J.K., Ball B.A., Mefford I.N., and Dedrick R.L. Quantitative microdialysis, analysis of transients and application to pharmacokinetics in brain. J. Neurochem. 57 (1991) 103-119
144. Namba H., Lucignani G., Nehlig A., Patlak C., Pettigrew K., Kennedy C., and Sokoloff L. Effects of insulin on hexose transport across blood-brain barrier in normoglycemia. Am. J. Physiol. 252 3 Pt 1 (1987) E299-E303
145. Nitsch C., and Klatzo I. Regional patterns of blood-brain barrier breakdown during epileptiform seizures induced by various convulsive agents. J. Neurol. Sci. 59 (1983) 305-322
146. Nottet H.S.L.M. Interactions between macrophages and brain microvascular endothelial cells, role in pathogenesis of HIV-1 infection and blood-brain barrier function. J. Neurovirol. 5 (1999) 659-669
147. Ohtaki K., Matsubara K., Fujimaru S., Shimizu K., Awaya T., Suno M., Chiba K., Hayase N., and Shiono H. Cefoselis, a beta-lactam antibiotic, easily penetrates the blood-brain barrier and causes seizure independently by glutamate release. J. Neural Transm. 111 12 (2004) 1523-1535
148. Oldendorf W.H. Lipid solubility and drug penetration of the blood-brain barrier. Proc. Exp. Biol. Med. 14 (1974) 813-816
149. Oldendorf W.H. Estimation of cerebral extraction of circulating compounds by the brain uptake index method, influence of circulation time, volume injection, and cerebral blood flow. Acta Physiol. Scand. 107 2 (1979) 153-159
150. Olson R.J., and Justice J.B. Quantitative microdialysis under transient conditions. Anal. Chem. 65 (1993) 1017-1022
151. Ooie T., Suzuki H., Terasaki T., and Sugiyama Y. Kinetic evidence for active efflux transport across the blood-brain barrier of quinolone antibiotics. J. Pharmacol. Exp. Ther. 283 (1997) 293-304
152. Pardridge W.M. Recent advances in blood-brain barrier transport. Ann. Rev. Pharmacol. Toxicol. 28 (1988) 25-39
153. Parsons L.H., and Justice Jr. J.B. Quantitative approaches to in vivo brain microdialysis. Crit. Rev. Neurobiol. 8 3 (1994) 189-220
154. Petito C.K., Schaefer J.A., and Plum F. Ultrastructural characteristics of the brain and blood-brain barrier in experimental seizures. Brain Res. 127 (1977) 251-267
155. Plock N., and Kloft C. Microdialysis-theoretical background and recent implementation in applied life-sciences. Eur. J. Pharm. Sci. 25 1 (2005) 1-24
156. Ponto-Boles L.L., and Ponto J.A. Uses and limitations of positron emission tomography in clinical pharmacokinetics/dynamics. Part I. Clin. Pharmacokinet. 22 (1992) 211-222
157. Ponto-Boles L.L., and Ponto J.A. Uses and limitations of positron emission tomography in clinical pharmacokinetics/dynamics. Part II. Clin. Pharmacokinet. 22 (1992) 274-283
158. Potschka H., Baltes S., and Loscher W. Inhibition of multidrug transporters by verapamil or probenecid does not alter blood-brain barrier penetration of levetiracetam in rats. Epilepsy Res. 58 2-3 (2004) 85-91
159. Potschka H., Fedrowitz M., and Loscher W. P-glycoprotein-mediated efflux of phenobarbital, lamotrigine, and felbamate at the blood-brain barrier, evidence from microdialysis experiments in rats. Neurosci. Lett. 327 3 (2002) 173-176
160. Potschka H., Fedrowitz M., and Loscher W. Brain access and anticonvulsant efficacy of carbamazepine, lamotrigine, and felbamate in ABCC2/MRP2-deficient TR-rats. Epilepsia 44 12 (2003) 1479-1486
161. 19F NMR study of trifluorothymidine metabolism in rat brain. NMR Biomed. 12 6 (1999) 373-380
162. Povlishock J.T. The pathophysiology of blood-brain barrier dysfunction due to traumatic brain injury. In: Pardridge W.M. (Ed). Introduction to the Blood-Brain Barrier; Methodology, Biology and Pathology (1998), Cambridge University Press, Cambridge, UK 441-453
163. 2- and COOH-proximal halves of the protein. J. Biol. Chem. 276 42 (2001) 38636-38644
164. Rapoport S.I., Ohno K., and Pettigrew K.D. Drug entry into the brain. Brain. Res. 172 (1979) 354-359
165. Rapoport S.I., and Robinson P.J. Tight junctional modification as the basis of osmotic opening of the blood-brain barrier. Ann. N.Y. Acad. Sci. 36 (1985) 251-267
166. Regina A., Koman A., Piciotti M., El Hafny B., Center M.S., Bergmann R., Couraud P.O., and Roux F. Mrp1 multidrug resistance-associated protein and P-glycoprotein expression in rat brain microvessel endothelial cells. J. Neurochem. 71 2 (1998) 705-715
167. Rubin L.L., and Staddon J.M. The cell biology of the blood-brain barrier. Annu. Rev. Neurosci. 22 (1999) 11-28
168. Ruggeri M., Zoli M., Grimaldi R., Ungerstedt U., Eliasson A., Agnati L.F., and Fuxe K. Aspects of neural plasticity in the central nervous system-III, methodological studies on the microdialysis technique. Neurochem. Int. 16 (1990) 427-443
169. Sawchuk R.J., and Elmquist W.F. Microdialysis in the study of drug transporters in the CNS. Adv. Drug Deliv. Rev. 45 (2000) 295-306
170. Sawchuk R.J., and Yang Z. Investigation of distribution, transport and uptake of anti-HIV drugs to the central nervous system. Adv. Drug Deliv. Rev. 39 (1999) 5-31
171. Schaddelee M.P., Groenendaal D., DeJongh J., Cleypool C.G., Ijzerman A.P., De Boer A.G., and Danhof M. Population pharmacokinetic modeling of blood-brain barrier transport of synthetic adenosine A1 receptor agonists. J. Pharmacol. Exp. Ther. 311 3 (2004) 1138-1146
172. Scheller D., and Kolb J. The internal reference technique in microdialysis: a practical approach to monitoring dialysis efficiency and to calculating tissue concentration from dialysate samples. J. Neurosci. Methods 40 (1991) 31-38
173. Schinkel A.H. The roles of P-glycoprotein and MRP1 in the blood-brain and blood-cerebrospinal fluid barriers. Adv. Exp. Med. Biol. 500 (2001) 365-372
174. Schinkel A.H., Smit J.J.M., Van Tellingen O., Beijnen J.H., Wagenaar E., Van Deemter L., Mol C.A.A.M., Van der Valk M.A., Robanus-Maandag E.C., Te Riele H.P.J., Berns A.J.M., and Borst P. Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell 77 (1994) 491-502
175. Schinkel A.H., Wagenaar E., Mol C.A.A.M., Van Deemter L., and Borst P. P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs. J. Clin. Invest. 97 (1996) 2517-2524
176. Schinkel A.H., Wagenaar E., Van Deemter L., Mol C.A.A.M., and Borst P. Absence of the mdr1a p-glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A. J. Clin. Invest. 96 (1995) 1698-1705
177. Scism J.L., Powers K.M., Artru A.A., Lewis L., and Shen D.D. Probenecid-inhibitable efflux transport of valproic acid in the brain parenchymal cells of rabbits: a microdialysis study. Brain Res. 884 1-2 (2000) 77-86
178. Shimizu K., Ohtaki K., Matsubara K., Aoyama K., Uezono T., Saito O., Suno M., Ogawa K., Hayase N., Kimura K., and Shiono H. Carrier-mediated processes in blood-brain barrier penetration and neural uptake of paraquat. Brain Res. 906 1-2 (2001) 135-142
179. Shuaib A.X., Crain B., Siren A.-L., Feuerstein G., Hallenbeck J., and Davis J.N. Assessment of damage from implantation of microdialysis probes in the rat hippocampus with silver degeneration staining. Neurosci. Lett. 112 (1990) 149-154
180. Smith Q.R. A review of blood-brain barrier transport techniques. Methods Mol. Med. 89 (2003) 193-208
181. Somjen G.G. Ion regulation in the brain, implications for pathophysiology. Neuroscientist 8 3 (2002) 254-267
182. Stahle L., and Borg N. Transport of alovudine (3′-fluorothymidine) into the brain and the cerebrospinal fluid of the rat, studied by microdialysis. Life Sci. 66 19 (2000) 1805-1816
183. Stain F., Barjavel M.J., Sandouk P., Plotkine M., Scherrmann J.-.M., and Bhargava H.N. Analgesic response and plasma and brain extracellular fluid pharmacokinetics of morphine and morpine-6-β d-glucuronide in the rat. J. Pharmacol. Exp. Ther. 274 (1995) 852-857
184. Stain-Texier F., Boschi G., Sandouk P., and Scherrmann J.M. Elevated concentrations of morphine 6-beta-d-glucuronide in brain extracellular fluid despite low blood-brain barrier permeability. Br. J. Pharmacol. 128 4 (1999) 917-924
185. Steward P.A., and Mikulis D. The blood-brain barrier in brain tumours. In: Pardridge W.M. (Ed). Introduction to the Blood-Brain Barrier; Methodology, Biology and Pathology (1998), Cambridge University Press 434-440
186. Sugiyama Y., Kusuhara H., and Suzuki H. Kinetic and biochemical analysis of carrier-mediated efflux of drugs through the blood-brain and blood-cerebrospinal fluid barriers, importance in the drug delivery to the brain. J. Control. Release 62 1-2 (1999) 179-186
187. Sun H., Bungay P.M., and Elmquist W.F. Effect of capillary efflux transport inhibition on the determination of probe recovery during in vivo microdialysis in the brain. J. Pharmacol. Exp. Ther. 297 3 (2001) 991-1000
188. Sun H., Dai H., Shaik N., and Elmquist W.F. Drug efflux transporters in the CNS. Adv. Drug Deliv. Rev. 55 1 (2003) 83-105
189. Sun H., Miller D.W., and Elmquist W.F. Effect of probenecid on fluorescein transport in the central nervous system using in vitro and in vivo models. Pharm. Res. 18 11 (2001) 1542-1549
190. Suzuki H., Terasaki T., and Sugiyama Y. Role of efflux transport across the blood-brain barrier and blood-cerebrospinal fluid barrier on the disposition of xenobiotics in the central nervous system. Adv. Drug Deliv. Rev. 25 (1997) 257-285
191. Takasato Y., Rapoport S.I., and Smith Q.R. An in situ brain perfusion technique to study cerebrovascular transport in the rat. Am. J. Physiol. 247 3 Pt 2 (1984) H484-H493
192. Takasawa K., Terasaki T., Suzuki H., and Sugiyama Y. In vivo evidence for carrier-mediated efflux transport of 3′-azido-3′-deoxythymidine and 2′,3′-dideoxyinosine across the blood-brain barrier via a probenecid-sensitive transport system. J. Pharmacol. Exp. Ther. 281 (1997) 369-375
193. Taylor E.M., Yan R., Hauptmann N., Maher T.J., Djahandideh D., and Glasky A.J. AIT-082, a cognitive enhancer, is transported into brain by a nonsaturable influx mechanism and out of brain by a saturable efflux mechanism. J. Pharmacol. Exp. Ther. 293 3 (2000) 813-821
194. Tofteng F., and Larsen F.S. Monitoring extracellular concentrations of lactate, glutamate, and glycerol by in vivo microdialysis in the brain during liver transplantation in acute liver failure. Liver Transpl. 8 3 (2002) 302-305
195. Tong X., and Patsalos P.N. A microdialysis study of the novel antiepileptic drug levetiracetam, extracellular pharmacokinetics and effect on taurine in rat brain. Br. J. Pharmacol. 133 6 (2001) 867-874
196. Tsai T.H., Lee C.H., and Yeh P.H. Effect of P-glycoprotein modulators on the pharmacokinetics of camptothecin using microdialysis. Br. J. Pharmacol. 134 6 (2001) 1245-1252
197. Tsuji A., and Tamai I. Carrier-mediated or specialized transport of drugs across the blood-brain barrier. Adv. Drug Deliv. Rev. 36 (1999) 277-290
198. Tunblad K., Ederoth P., Gardenfors A., Hammarlund-Udenaes M., and Nordstrom C.H. Altered brain exposure of morphine in experimental meningitis studied with microdialysis. Acta Anaesthesiol. Scand. 48 3 (2004) 294-301
199. Tunblad K., Hammarlund-Udenaes M., and Jonsson E.N. Influence of probenecid on the delivery of morphine-6-glucuronide to the brain. Eur. J. Pharm. Sci. 24 1 (2005) 49-57
200. Tunblad K., Jonsson E.N., and Hammarlund-Udenaes M. Morphine blood-brain barrier transport is influenced by probenecid co-administration. Pharm. Res. 20 4 (2003) 618-623
201. Turner G. Cerebral malaria and brain microvasculature. In: Pardridge W.M. (Ed). Introduction to the Blood-Brain Barrier; Methodology, Biology and Pathology (1998), Cambridge University Press, Cambridge, UK 454-461
202. Van Bree J.B., Heijligers-Feijen C.D., de Boer A.G., Danhof M., and Breimer D.D. Stereoselective transport of baclofen across the blood-brain barrier in rats as determined by the unit impulse response methodology. Pharm. Res. 8 2 (1991) 259-262
203. Vogelgesang S., Cascorbi I., Schroeder E., Pahnke J., Kroemer H.K., Siegmund W., Kunert-Keil C., Walker L.C., and Warzok R.W. Deposition of Alzheimer's beta-amyloid is inversely correlated with P-glycoprotein expression in the brains of elderly non-demented humans. Pharmacogenetics 12 7 (2002) 535-541
204. Vorbrodt A.W. Ultrastrucutral cytochemistry of blood-brain barrier endothelia. Prog. Histochem. Cytochem. 18 (1988) 1-99
205. Walker M.C., Tong X., Perry H., Alavijeh M.S., and Patsalos P.N. Comparison of serum, cerebrospinal fluid and brain extracellular fluid pharmacokinetics of lamotrigine. Br. J. Pharmacol. 130 (2000) 242-248
206. Wallace M.C., Teasdale G.M., and McCullough J. Autoradiographic analysis of 3H-MK-801 (dizocilpine) in vivo uptake and in vitro binding after focal cerebral ischemia in the rat. J. Neurosurg. 76 (1992) 127-133
207. Westergren I., Nystrom B., Hamberger A., and Johansson B.B. Intracerebral microdialysis and the blood-brain barrier. J. Neurochem. 64 (1995) 229-234
208. Wijnholds J. Drug resistance caused by multidrug resistance-associated proteins. Novartis Found Symp. 243 (2002) 69-79 discussion 80-82, 180-185
209. Williams S.A., Davson H., and Segal M.B. Transport of the nucleoside thymidine, in the central nervous system, the blood-cerebrospinal fluid and blood-brain barriers. In: Greenwood J., Begley D.J., and Segal M.B. (Eds). New Concepts of a Blood-Brain Barrier (1995), Plenum Press, New York and London 175-188
210. Xie R., and Hammarlund-Udenaes M. Blood-brain barrier equilibration of codeine in rats studied with microdialysis. Pharm. Res. 15 4 (1998) 570-575
211. Xie R., Bouw M.R., and Hammarlund-Udenaes M. Modelling of the blood-brain barrier transport of morphine-3-glucuronide studied using microdialysis in the rat, involvement of probenecid-sensitive transport. Br. J. Pharmacol. 131 8 (2000) 1784-1792
212. Xie R., Hammarlund-Udenaes M., de Boer A.G., and de Lange E.C.M. The role of P-glycoprotein in blood-brain barrier transport of morphine, transcortical microdialysis studies in mdr1a (-/-) and mdr1a (+/+) mice. Br. J. Pharmacol. 128 (1999) 563-568
213. Yokel R.A. Brain uptake, retention, and efflux of aluminum and manganese. Environ. Health Perspect. 110 Suppl 5 (2002) 699-704
214. Yokel R.A., Allen D.D., Burgio D.E., and McNamara P.J. Antipyrine as a dialyzable reference to correct differences in efficiency among and within sampling devices during in vivo microdialysis. J. Pharmacol. Toxicol. Methods 27 (1992) 135-142
215. Yu D.-W., Gatley S.J., Wolf A.P., MacGregor R.R., Dewey S.L., Fowle J.S., and Schlyer D.J. Synthesis of carbon-11 labeled ionidated cocaine derivatives and their distribution in baboon brain measured using positron emission tomography. J. Med. Chem. 35 (1992) 2178-2183
216. Zhang Y., Han H., Elmquist W.F., and Miller D.W. Expression of various multidrug resistance-associated protein (MRP) homologues in brain microvessel endothelial cells. Brain Res. 876 1-2 (2000) 148-153